Research plays a key part in moving health care forward. MEDNAX established the Center for Research, Education, Quality and Safety (CREQS) to further the company’s mission to take great care of the patient, every day and in every way. Each year, our clinicians participate in and publish clinical research to advance their knowledge as well as their colleagues and the general public. Today, we highlight a small fraction of the great work published by our clinicians so far this year.
Kaashif A. Ahmad, M.D., participated in “A Randomized Trial of Erythropoietin for Neuroprotection in Preterm Infants,” which resulted in establishing evidence that high-dose erythropoietin treatment administered to extremely preterm infants from 24 hours after birth through 32 weeks of postmenstrual age did not result in a lower risk of severe neurodevelopmental impairment or death at two years of age.
Veeral N. Tolia, M.D., Kaashif A. Ahmad, M.D., Jack Jacob, M.D., Amy S. Kelleher, MSHS, and Reese H. Clark, M.D., part of the MEDNAX ROP Registry Investigators, co-authored “Two-Year Outcomes of Infants With Stage 2 or Higher Retinopathy of Prematurity: Results From a Large Multicenter Registry.”
Recognizing congenital heart defects are a leading cause of neonatal morbidity and mortality, C. Andrew Combs, M.D., and cohorts propose quality metrics to measure prenatal detection of these defects.
Our neonatal and perinatal specialists strive to improve patient outcomes, including reducing the risk of neonatal morbidity. Emily Hamilton, M.D., and Kimberly Maurel, CNS, R.N., worked on the study “Estimating risk of severe neonatal morbidity in preterm births under 32 weeks of gestation,” which showed ways to better estimate the risk for severe neonatal morbidity.
There are many important players in maternal health care and knowing where responsibilities lie is essential for establishing safe and quality protocols. C. Andrew Combs, M.D., whose special interests include maternal medical problems such as preeclampsia, hypertension, cardiac, and renal disease, assisted in creating “Who's Who in Patient Safety and Quality for Maternal Healthcare in the United States.”
You can view more of our clinician’s outstanding research here.
All questions regarding Research Applications should be directed to mednax_research@mednax.com.